UY35610A - Derivados de prodroga de triazolpiridinas sustituidas - Google Patents

Derivados de prodroga de triazolpiridinas sustituidas

Info

Publication number
UY35610A
UY35610A UY0001035610A UY35610A UY35610A UY 35610 A UY35610 A UY 35610A UY 0001035610 A UY0001035610 A UY 0001035610A UY 35610 A UY35610 A UY 35610A UY 35610 A UY35610 A UY 35610A
Authority
UY
Uruguay
Prior art keywords
derivatives
triazolpiridines
substituted
production
prophylaxis
Prior art date
Application number
UY0001035610A
Other languages
English (en)
Inventor
Dr Michael Brüning
Dr Hans-Georg Lerchen
Dr Donald Bierer
Krenz Ursula
Dr Volker Schulze
Dr Dirk Kosemund
Dr Antje Margret Wengner
Dr Gerhard Siemeister
Dr Detlef Stöckigt
Dr Philip Lienau
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of UY35610A publication Critical patent/UY35610A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Derivados de prodroga de la fórmula general (I) procesos para su preparación y su uso en el tratamiento y/o la profilaxis de enfermedades.
UY0001035610A 2013-06-11 2014-06-11 Derivados de prodroga de triazolpiridinas sustituidas UY35610A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13171508 2013-06-11

Publications (1)

Publication Number Publication Date
UY35610A true UY35610A (es) 2015-01-30

Family

ID=48576905

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035610A UY35610A (es) 2013-06-11 2014-06-11 Derivados de prodroga de triazolpiridinas sustituidas

Country Status (35)

Country Link
US (1) US9586958B2 (es)
EP (1) EP3008062B1 (es)
JP (1) JP2016526534A (es)
KR (1) KR20160019492A (es)
CN (1) CN105377848A (es)
AP (1) AP2015008898A0 (es)
AR (1) AR096585A1 (es)
AU (1) AU2014280356A1 (es)
CA (1) CA2914745A1 (es)
CL (1) CL2015003605A1 (es)
CR (1) CR20150659A (es)
CU (1) CU20150176A7 (es)
DK (1) DK3008062T3 (es)
DO (1) DOP2015000299A (es)
EA (1) EA201600002A1 (es)
ES (1) ES2626790T3 (es)
HK (1) HK1221955A1 (es)
HR (1) HRP20170717T1 (es)
HU (1) HUE033131T2 (es)
IL (1) IL242847A0 (es)
LT (1) LT3008062T (es)
MA (1) MA38654B1 (es)
MX (1) MX2015017119A (es)
NI (1) NI201500176A (es)
PE (1) PE20160156A1 (es)
PH (1) PH12015502746A1 (es)
PL (1) PL3008062T3 (es)
PT (1) PT3008062T (es)
RS (1) RS56034B1 (es)
SG (1) SG11201509858QA (es)
SI (1) SI3008062T1 (es)
TN (1) TN2015000545A1 (es)
UY (1) UY35610A (es)
WO (1) WO2014198647A2 (es)
ZA (1) ZA201508868B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41136A (fr) * 2014-12-09 2017-10-17 Bayer Pharma AG Composés pour le traitement d'un cancer
CN107567503B (zh) 2015-04-17 2022-03-22 荷兰转化研究中心有限责任公司 用于ttk抑制剂化疗的预后生物标记
CN109310686B (zh) 2016-04-04 2022-06-21 凯莫森特里克斯股份有限公司 可溶性C5aR拮抗剂
WO2023113478A1 (en) * 2021-12-15 2023-06-22 Sillajen, Inc. Methods of treating neoplastic diseases

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69736711T2 (de) 1996-08-28 2007-09-20 Pfizer Inc. Substituierte 6,5-heterobicyclische-derivate
SI0991628T1 (en) 1997-05-28 2005-06-30 Aventis Pharmaceuticals Inc QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56lck TYROSINE KINASES
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
JP2004346016A (ja) 2003-05-22 2004-12-09 Otsuka Chemical Co Ltd トリフルオロメチルキノキサリン化合物、その製造方法、及び有害生物防除剤
AU2004275694B2 (en) 2003-06-30 2008-03-06 Bizbiotech Co., Ltd. Compounds, compositions and methods
BRPI0516819A (pt) 2004-10-07 2008-09-23 Warner Lambert Co derivados de triazolopiridina e agentes antibacterianos
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2007065010A2 (en) 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
WO2007138072A2 (en) 2006-05-31 2007-12-06 Galapagos N.V. Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases
EP2056829B9 (en) 2006-08-16 2012-09-26 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
ES2549862T3 (es) 2006-08-30 2015-11-02 Cellzome Limited Derivados de triazol como inhibidores de quinasa
PE20090288A1 (es) 2007-05-10 2009-04-03 Smithkline Beecham Corp Derivados de quinoxalina como inhibidores de la pi3 quinasa
AU2008277628B2 (en) 2007-07-18 2012-03-15 Novartis Ag Bicyclic heteroaryl compounds and their use as kinase inhibitors
JP2010535804A (ja) 2007-08-09 2010-11-25 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害薬としてのキノキサリン誘導体
JP2010536841A (ja) 2007-08-23 2010-12-02 アストラゼネカ アクチボラグ 増殖性疾患治療のためのｔｔｋ／ｍｐｓ１阻害剤としての２−アニリノプリン−８−オン類
US8263595B2 (en) 2007-08-31 2012-09-11 Merck Serono Sa Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
US8865699B2 (en) 2007-11-27 2014-10-21 Cellzome Ltd. Amino triazoles as PI3K inhibitors
EP2307400B1 (en) 2008-05-30 2014-04-23 Amgen, Inc Inhibitors of pi3 kinase
TWI491610B (zh) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
WO2010092015A1 (en) 2009-02-10 2010-08-19 Cellzome Limited Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors
SG173610A1 (en) 2009-02-13 2011-09-29 Fovea Pharmaceuticals Sa [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors
JP6168773B2 (ja) 2009-04-29 2017-07-26 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾキノキサリン
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
EP2473498A1 (en) 2009-09-04 2012-07-11 Bayer Pharma Aktiengesellschaft Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
EP2343294A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343295A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
EP2343297A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
US9145399B2 (en) 2010-01-15 2015-09-29 Janssen Pharmaceuticals, Inc. Substituted bicyclic triazole derivatives as gamma secretase modulators
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
SI2699575T1 (sl) 2011-04-21 2015-10-30 Bayer Intellectual Property Gmbh Triazolopiridini
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
JP6166289B2 (ja) 2012-03-14 2017-07-19 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾピリダジン
CN104603136B (zh) * 2012-07-10 2017-06-27 拜耳医药股份有限公司 制备取代的三唑并吡啶的方法
AR096469A1 (es) * 2013-06-06 2015-12-30 Bayer Pharma AG Composiciones farmacéuticas que comprenden compuestos del tipo triazolpiridinas
CN105431435A (zh) * 2013-06-07 2016-03-23 拜耳制药股份公司 具有作为mps-1抑制剂的活性的取代的三唑并吡啶类
SG11201509351UA (en) * 2013-06-10 2015-12-30 Bayer Pharma AG Novel compounds for the treatment of cancer
MX2015017120A (es) * 2013-06-11 2016-10-05 Bayer Pharma AG Combinaciones para el tratamiento de cancer que comprende un inhibidor de la quinasa mps-1 y un inhibidor de la mitosis.

Also Published As

Publication number Publication date
AR096585A1 (es) 2016-01-20
PE20160156A1 (es) 2016-04-20
HUE033131T2 (en) 2017-11-28
LT3008062T (lt) 2017-06-12
EP3008062A2 (en) 2016-04-20
US9586958B2 (en) 2017-03-07
SI3008062T1 (sl) 2017-06-30
ZA201508868B (en) 2017-08-30
US20160207915A1 (en) 2016-07-21
JP2016526534A (ja) 2016-09-05
AU2014280356A1 (en) 2015-12-24
PT3008062T (pt) 2017-06-07
MX2015017119A (es) 2016-04-06
MA38654B1 (fr) 2018-11-30
EP3008062B1 (en) 2017-04-05
CN105377848A (zh) 2016-03-02
RS56034B1 (sr) 2017-09-29
TN2015000545A1 (en) 2017-04-06
DOP2015000299A (es) 2016-03-15
PH12015502746A1 (en) 2016-03-21
HK1221955A1 (zh) 2017-06-16
SG11201509858QA (en) 2015-12-30
HRP20170717T1 (hr) 2017-07-28
WO2014198647A2 (en) 2014-12-18
IL242847A0 (en) 2016-02-01
KR20160019492A (ko) 2016-02-19
CL2015003605A1 (es) 2016-06-24
DK3008062T3 (en) 2017-06-12
NI201500176A (es) 2016-01-06
CU20150176A7 (es) 2016-05-30
WO2014198647A3 (en) 2015-02-05
EA201600002A1 (ru) 2016-06-30
CA2914745A1 (en) 2014-12-18
AP2015008898A0 (en) 2015-12-31
CR20150659A (es) 2016-01-29
ES2626790T3 (es) 2017-07-26
PL3008062T3 (pl) 2017-08-31

Similar Documents

Publication Publication Date Title
NI201700096A (es) Derivados de 4h-pirrol[3, 2-c]piridin-4-ona
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
MX2017006302A (es) Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
ECSP14013284A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
MX2015010125A (es) Derivados de piridazinona-amidas.
UY35344A (es) Oestra-1,3,5(10),16-tetraeno-3-carboxamidas
CR20160133A (es) Derivados de fenilalanina sustituidos
UY34615A (es) Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias.
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
NI201500175A (es) Compuestos nuevos para el tratamiento del cáncer
CR20150659A (es) Derivados de prodroga de triazolpiridinas sustituidas
CL2015003431A1 (es) Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales
UY37671A (es) N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso
CL2016001054A1 (es) Compuestos para el tratamiento de diabetes y complicaciones de enfermedades derivadas de la misma
DOP2016000325A (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas
NI201500172A (es) Composiciones farmacéuticas
DOP2015000290A (es) Benzoxazoles sustituidos
NI201700072A (es) Compuestos para tratar el cáncer.
UY35715A (es) Proceso para preparar dronedarona y sales de la misma

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211206